Want to see RAPP full AI Analyst Report?

Rapport Therapeutics, Inc. (RAPP) Stock Forecast & Price Target

172 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RAPP Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Rapport

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RAPP Stock 12 Month Forecast

Average Price Target

$69.40

▲(32.19% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Rapport Therapeutics, Inc. in the last 3 months. The average price target is $69.40 with a high forecast of $91.00 and a low forecast of $50.00. The average price target represents a 32.19% change from the last price of $52.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","59":"$59","92":"$92","42.5":"$42.5","75.5":"$75.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$91.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,42.5,59,75.5,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,37.30461538461538,41.779230769230765,46.253846153846155,50.72846153846154,55.20307692307692,59.67769230769231,64.15230769230769,68.62692307692308,73.10153846153847,77.57615384615384,82.05076923076923,86.52538461538461,{"y":91,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,35.64307692307692,38.456153846153846,41.26923076923077,44.082307692307694,46.895384615384614,49.708461538461535,52.52153846153846,55.33461538461539,58.14769230769231,60.96076923076923,63.77384615384616,66.58692307692309,{"y":69.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.83,34.15076923076923,35.47153846153846,36.79230769230769,38.113076923076925,39.433846153846154,40.754615384615384,42.075384615384614,43.396153846153844,44.71692307692308,46.03769230769231,47.35846153846154,48.67923076923077,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.37,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.89,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.11,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.56,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.83,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$91.00

Average Price Target$69.40

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Walsh

JonesTrading

$50→$82

Buy

56.19%

Upside

Reiterated

10/21/26

Analysts' Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)

Salveen Richter

Goldman Sachs

$62→$68

Buy

29.52%

Upside

Reiterated

10/21/26

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from Goldman Sachs

Benjamin Burnett

Wells Fargo

$51→$50

Buy

-4.76%

Downside

Assigned

10/21/26

Wells says Rapport's RAP-219 efficacy looks good, flags some questions on safetyWells says Rapport's RAP-219 efficacy looks good, flags some questions on safety

Douglas Tsao

H.C. Wainwright

$40→$66

Buy

25.71%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $66 from $40 at H.C. WainwrightRapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright

Jason Butler

Citizens JMP

$80→$91

Buy

73.33%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $91 from $80 at CitizensRapport Therapeutics price target raised to $91 from $80 at Citizens

Tiago Fauth

Raymond James

$75→$86

Buy

63.81%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $86 from $75 at Raymond JamesRapport Therapeutics price target raised to $86 from $75 at Raymond James

Delma Caiati

Guggenheim

$65→$70

Buy

33.33%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $70 from $65 at GuggenheimRapport Therapeutics price target raised to $70 from $65 at Guggenheim

Rudy Li

Wolfe Research

$50

Buy

-4.76%

Downside

Initiated

10/15/26

Rapport Therapeutics initiated with an Outperform at Wolfe ResearchRapport Therapeutics initiated with an Outperform at Wolfe Research

Kambiz Yazdi

BTIG

$75

Buy

42.86%

Upside

Reiterated

10/01/26

BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Myles Minter

William Blair

―

Buy

―

Reiterated

09/23/26

RAPP: Buy Initiation Backed by RAP-219 Clinical Progress and Mechanistic Differentiation

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/23/26

Analysts Offer Insights on NA Companies: Andersen Group, Inc. Class A (NYSE: ANDG) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

09/22/26

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from TD Cowen

Paul Matteis

Stifel Nicolaus

$56

Buy

6.67%

Upside

Reiterated

09/16/26

Analysts Offer Insights on NA Companies: Jack Henry & Associates (NASDAQ: JKHY) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Marc Goodman

Leerink Partners

$52

Buy

-0.95%

Downside

Initiated

06/24/26

Rapport Therapeutics initiated with an Outperform at LeerinkRapport Therapeutics initiated with an Outperform at Leerink

Joon Lee

UBS

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on NA Companies: Kyivstar Group (NASDAQ: KYIV) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Walsh

JonesTrading

$50→$82

Buy

56.19%

Upside

Reiterated

10/21/26

Analysts' Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)

Salveen Richter

Goldman Sachs

$62→$68

Buy

29.52%

Upside

Reiterated

10/21/26

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from Goldman Sachs

Benjamin Burnett

Wells Fargo

$51→$50

Buy

-4.76%

Downside

Assigned

10/21/26

Wells says Rapport's RAP-219 efficacy looks good, flags some questions on safetyWells says Rapport's RAP-219 efficacy looks good, flags some questions on safety

Douglas Tsao

H.C. Wainwright

$40→$66

Buy

25.71%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $66 from $40 at H.C. WainwrightRapport Therapeutics price target raised to $66 from $40 at H.C. Wainwright

Jason Butler

Citizens JMP

$80→$91

Buy

73.33%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $91 from $80 at CitizensRapport Therapeutics price target raised to $91 from $80 at Citizens

Tiago Fauth

Raymond James

$75→$86

Buy

63.81%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $86 from $75 at Raymond JamesRapport Therapeutics price target raised to $86 from $75 at Raymond James

Delma Caiati

Guggenheim

$65→$70

Buy

33.33%

Upside

Reiterated

10/20/26

Rapport Therapeutics price target raised to $70 from $65 at GuggenheimRapport Therapeutics price target raised to $70 from $65 at Guggenheim

Rudy Li

Wolfe Research

$50

Buy

-4.76%

Downside

Initiated

10/15/26

Rapport Therapeutics initiated with an Outperform at Wolfe ResearchRapport Therapeutics initiated with an Outperform at Wolfe Research

Kambiz Yazdi

BTIG

$75

Buy

42.86%

Upside

Reiterated

10/01/26

BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Myles Minter

William Blair

―

Buy

―

Reiterated

09/23/26

RAPP: Buy Initiation Backed by RAP-219 Clinical Progress and Mechanistic Differentiation

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/23/26

Analysts Offer Insights on NA Companies: Andersen Group, Inc. Class A (NYSE: ANDG) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

09/22/26

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from TD Cowen

Paul Matteis

Stifel Nicolaus

$56

Buy

6.67%

Upside

Reiterated

09/16/26

Analysts Offer Insights on NA Companies: Jack Henry & Associates (NASDAQ: JKHY) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Marc Goodman

Leerink Partners

$52

Buy

-0.95%

Downside

Initiated

06/24/26

Rapport Therapeutics initiated with an Outperform at LeerinkRapport Therapeutics initiated with an Outperform at Leerink

Joon Lee

UBS

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on NA Companies: Kyivstar Group (NASDAQ: KYIV) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rapport Therapeutics, Inc.

3 Months

Joseph ThomeTD Cowen

Success Rate

10/16 ratings generated profit

Average Return

+4.39%

Copying Joseph Thome's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +4.39% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

5/11 ratings generated profit

Average Return

+33.20%

Copying Paul Matteis's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +33.20% per trade.

2 Years

Paul MatteisStifel Nicolaus

Success Rate

6/11 ratings generated profit

Average Return

+32.08%

Copying Paul Matteis's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +32.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RAPP Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RAPP has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RAPP average Analyst price target in the past 3 months is 69.40.

Each month's total comprises the sum of three months' worth of ratings.

RAPP Financial Forecast

RAPP Earnings Forecast

Next quarter’s earnings estimate for RAPP is -$1.20 with a range of -$1.36 to -$1.02. The previous quarter’s EPS was -$1.19. RAPP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.

RAPP Sales Forecast

Next quarter’s sales forecast for RAPP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RAPP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year RAPP has Performed in-line its overall industry.

RAPP Stock Forecast FAQ

What is RAPP’s average 12-month price target, according to analysts?

Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is 69.40.

What is RAPP’s upside potential, based on the analysts’ average price target?

Rapport Therapeutics, Inc. has 32.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RAPP a Buy, Sell or Hold?

Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Rapport Therapeutics, Inc.’s price target?

The average price target for Rapport Therapeutics, Inc. is 69.40. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $91.00 ,the lowest forecast is $50.00. The average price target represents 32.19% Increase from the current price of $52.5.

What do analysts say about Rapport Therapeutics, Inc.?

Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of RAPP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Rapport Therapeutics, Inc. (RAPP) Stock Forecast & Price Target

RAPP Analyst Ratings

RAPP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rapport Therapeutics, Inc.

RAPP Analyst Recommendation Trends

RAPP Financial Forecast

RAPP Earnings Forecast

RAPP Sales Forecast

RAPP Stock Forecast FAQ

Detailed List of Analyst Forecasts